Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

about

Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

P2860

Q50049497-5F1BB807-8686-461B-AE57-965BBE7CE66B

P2860

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

Item

http://www.wikidata.org/entity/Q39111080

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

@en

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

@nl

type

Item

label

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

@en

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

@nl

prefLabel

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

@en

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

@nl

P1476

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

@en

P2093

Alison P Duffy

http://www.w3.org/2001/XMLSchema#string

James A Trovato

http://www.w3.org/2001/XMLSchema#string

Kristine L Keller

http://www.w3.org/2001/XMLSchema#string

Miguel J Franquiz

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Drug-induced prolongation of the QT interval.

Clinical pharmacokinetics of tyrosine kinase inhibitors.

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.

Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?

Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.

Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.

P31

scholarly article

P356

10.1177/1078155216682311

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27941080

http://www.w3.org/2001/XMLSchema#string

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

about

P2860

P2860

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698